| abstract |
A novel NF-κB-inhibiting substance, and a pharmaceutical composition containing the same for preventing or ameliorating a disease caused by NF-κB activation, an apoptosis-inducing agent, and a mononuclear cell To provide an activation inhibitor, an IκB expression induction inhibitor, and a kit. A compound represented by the following general formula (I) (wherein R 1 is a hydrogen atom or an alkyl group in formula (I)) inhibits the activation of NF-κB, and has apoptosis. It has an action to induce, an action to inhibit activation of mononuclear cells, an action to inhibit expression induction of IκB accompanying the activation of NF-κB, and the like. [Selection figure] None |